Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX10 plus chemotherapy in extensive stage small cell lung cancer
NCT04063163Phase 3Completed
- Sponsor
- Henlius
- Start
- Sep 2019
- Primary completion
- May 2024
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial in small cell lung cancer (SCLC) comparing Arm A: HLX10 + Chemotherapy with Arm B: Placebo + Chemotherapy (2 arms). Primary endpoint: Overall Survival at 56 months. Started Sep 2019; status: completed.
02
Drugs
serplulimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04063163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04063163.